A RANDOMIZED PHASE II TRIAL OF MEK INHIBITOR SELUMETINIB (AZD6244) COMBINED CONTINUOUSLY OR SEQUENTIALLY WITH CISPLATIN/GEMCITABINE (CIS/GEM) VERSUS CIS/GEM ALONE IN PATIENTS WITH ADVANCED BILIARY CANCER

Registry ID

BIL-MEK

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

PRINCESS MARGARET CANCER CENTRE

Start date

2016-05-25

Completion date

2025-06-25

Last update

2014-06-27

Conditions

• BILIARY CANCER

Related clinical trials

• PHASE III, RANDOMIZED, OPEN-LABEL, GLOBAL, MULTICENTER STUDY OF RILVEGOSTOMIG OR DURVALUMAB IN COMBINATION WITH CHEMOTHERAPY AS A FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED BILIARY TRACT CANCER (ARTEMIDE-BILIARY02)
• BEAMION PANTUMOR-1: A PHASE II, MULTICENTRE, MULTICOHORT, OPEN LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZONGERTINIB (BI 1810631) FOR THE TREATMENT OF SELECTED HER2-MUTATED OR OVEREXPRESSED/AMPLIFIED SOLID TUMOURS
• "A PHASE 3 RANDOMIZED, DOUBLE BLIND STUDY OF PEMBROLIZUMAB PLUS GEMCITABINE/CISPLATIN VERSUS PLACEBO PLUS GEMCITABINE/CISPLATIN AS FIRST-LINE THERAPY IN PARTICIPANTS WITH ADVANCED AND/OR UNRESECTABLE BILIARY TRACT CARCINOMA.
• A MULTICENTRE, OPEN-LABEL PHASE II STUDY OF NAB-PACLITAXEL IN COMBINATION WITH GEMCITABINE + CISPLATIN AS FIRST LINE TREATMENT IN PATIENTS WITH UNRESECTABLE BILIARY TRACT CANCER

View on source registry